- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback